Caremark Cease and Desist Letters – Trudhesa®

PAAS National® analysts have recently assisted a few pharmacies that received “Cease and Desist” Letters from Caremark related to dispensing Trudhesa® nasal spray for migraines. The strongly worded letters alleged that pharmacies were in violation of the Provider Agreement and various sections of the Provider Manual.

Become an audit assistance member today to continue reading this article. As a member, you’ll have access to hundreds of articles and receive our monthly proactive newsletter!

Caremark alleged that pharmacies had allowed a “pharmaceutical hub” to use the pharmacy’s identity or billing information to submit claims and outsourced the collection of patient copays. Additionally, Caremark demanded that pharmacies immediately cease these violating actions and reverse all offending prescription claims.

Purportedly, all prescriptions for Trudhesa® were received as transfers from a hub pharmacy such as Phil, Carepoint Pharmacy, or ASPN pharmacies which appear to be “digital pharmacies” and the only way that Trudhesa® is available per the manufacturer website.

Pharmacies that are not responsive to Caremark’s demands may face network termination.

PAAS Tips:

  • Be very cautious when receiving transfer prescriptions from hub pharmacies
  • Review Caremark Provider Manual section 4.12 to learn about acceptable practices related to pharmaceutical hubs
Eric Hartkopf, PharmD